A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
    Completely Resected High-risk Melanoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) In order to participate in this study, you must have a confirmed diagnosis of melanoma that has been completely removed through surgery (must be in stage IIC, III, or IV) <

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Uveal melanoma
    2. 2) Any evidence of remaining disease after surgery by imaging, pathology, or cytology
    3. 3) Human immunodeficiency virus (HIV), hepatitis B (HBV), or


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.